Stopped: Study was closed due to Sponsor switched to Longeveron. New Identifier is NTC03525418
This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Monitor major adverse cardiac events
Timeframe: 1 month after injection